论文部分内容阅读
化学名 (-)-(R)-1-(对-羟苯基)-2-[(3,4-二甲氧苯乙基)氨基]乙醇药效分类慢性心衰治疗药开发单位 (日)田边制药(株) 上市厂商 (日)田边制药(株),1987年10月2日上市。药理本品选择性地刺激肾上腺素能β_1受体,可使心肌收缩力持续加强。对β_2和α受体几无刺激作用,所以几乎不影响β_2优势的心搏数。本品作用特征是扩张冠脉血管,与洋地黄比不易引起心律不齐。药动学人口服本品1小时内达最高血药浓度,消除半衰期约4小时。人和动物连续给药,体内无蓄积性。血中主要以本品原
(R) -1- (p-hydroxyphenyl) -2 - [(3,4-dimethoxyphenethyl) amino] ethanol Pharmacodynamic classification Chronic heart failure treatment drug development unit ) Tanabe Pharmaceutical Co., Ltd. listed manufacturer (Japan) Tanabe Pharmaceutical Co., Ltd., October 2, 1987 listed. Pharmacological This product selectively stimulate adrenergic β 1 receptors, myocardial contractility can continue to strengthen. There is no stimulation of beta 2 and alpha receptors, so there is almost no effect on beta 2 predominance. This product is characterized by the role of dilation of coronary vessels, and digitalis is not easy to cause arrhythmia. Pharmacokinetic oral administration of this product within 1 hour reached the highest plasma concentration, elimination half-life of about 4 hours. Continuous administration of human and animals, the body without accumulating. The main blood to the original product